NASDAQ$RMTI

Rockwell Medical Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Announced third quarter 2023 results and reported becoming the leading supplier of liquid bicarbonate hemodialysis concentrates in the United States.

Rockwell Medical announced its Q3 2023 results, highlighting its success in becoming the leading supplier of liquid bicarbonate hemodialysis concentrates in the US and its expectation to be profitable on an adjusted EBITDA basis in Q4 2023. The company also expects net sales for 2023 to be between $82.0 million and $86.0 million, representing a 17% to 18% year-over-year increase, and gross profit to be between $8.0 million and $10.0 million, representing a 95% to 144% year-over-year increase.

  • Rockwell Medical became the leading supplier of liquid bicarbonate hemodialysis concentrates in the United States.
  • The company now services approximately one-third of all purchasing facilities, including outpatient dialysis clinics and hospitals.
  • Rockwell Medical continues to evaluate potential business development opportunities.
  • Company expects to be profitable on an adjusted EBITDA basis in the fourth quarter of 2023.

Headline financials

Total Revenue

$23.8M

Previous: $18.7M+27.2%
EPS (adj)

-$0.07

Previous: -$0.40+82.5%
Capital Expenditures

-$12.4M

Previous: -$197K-6182.7%
Free Cash Flow

-$1.87M

Previous: -$4.39M+57.3%
Net Income

-$1.87M

Previous: -$4.19M+55.3%
Operating Income

-$1.74M

Previous: -$3.71M+53.2%
Gross Profit

$2.2M

Previous: $777K+183.4%
Cash & Equivalents

$7.76M

Previous: $13M-40.2%
Total Assets

$52.6M

Previous: $54.2M-2.9%
R&D Expense

$494K

No prior period
Stock-Based Comp

$212K

Previous: $177K+19.8%

Revenue & EPS history

Rockwell Medical · Revenue · Quarterly

$23.8M

Q3 2023+27.2%vs Q3 2022
Beat estimate in 8 of 13 quarters(62%)
ActualEstimate

Forward guidance

The Company expects net sales for 2023 to be between $82.0 million and $86.0 million, which represents an increase of 17% to 18% year-over-year. The Company expects gross profit for 2023 to be between $8.0 million and $10.0 million, which represents an increase of 95% to 144% year-over-year. Rockwell Medical now expects to be profitable on an adjusted EBITDA basis in the fourth quarter of 2023.

Tailwinds

  • Net sales for 2023 expected to be between $82.0 million and $86.0 million.
  • Net sales represent an increase of 17% to 18% year-over-year.
  • Gross profit for 2023 expected to be between $8.0 million and $10.0 million.
  • Gross profit represents an increase of 95% to 144% year-over-year.
  • Rockwell Medical now expects to be profitable on an adjusted EBITDA basis in the fourth quarter of 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

-3.1%

Avg return

Earnings day

-3.3%

Avg return

5 days after

-3.0%

Avg return

30 days after

38%

24 / 63 earnings

Positive

+28.2%

Q3 2022

Best reaction

-43.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-13.0%-11.3%
Q1 2026-3.6%+2.8%-18.2%
Q3 2025-9.2%-17.1%-12.4%
Q1 2025-6.4%-9.8%-11.6%
Q4 2024-20.5%-31.8%-41.5%
Q3 2024-43.4%-49.2%-55.5%
Q2 2024+22.6%+35.6%+68.4%
Q1 2024+0.6%+4.1%+8.2%
Q4 2023+3.6%+0.0%-12.1%
Q3 2023+12.2%+5.1%-11.2%
Q2 2023-7.4%-25.8%-28.5%
Q1 2023-4.5%-3.7%+71.8%
Q4 2022+14.6%+18.4%+74.7%
Q3 2022+28.2%+19.4%+0.0%
Q2 2022+12.0%+7.1%-14.1%
Q1 2022+3.0%-17.3%-34.7%
Q4 2021-13.6%-11.4%-27.3%
Q3 2021-7.7%-7.7%-21.2%
Q2 2021-6.2%-10.8%-4.6%
Q1 2021-2.2%-4.3%+0.0%
Q4 2020+4.5%-1.8%-13.5%
Q3 2020+1.1%+5.6%+33.7%
Q2 2020+4.2%+0.0%-26.3%
Q1 2020-4.7%-12.9%-9.0%
Q4 2019-42.7%-25.0%-22.6%
Q3 2019+5.4%+12.4%+23.7%
Q2 2019-5.6%+2.0%+9.3%
Q1 2019-7.5%-11.9%-25.6%
Q4 2018+3.0%+23.9%+4.7%
Q3 2018+8.9%+12.3%-16.2%
Q2 2018-15.5%-12.4%-13.6%
Q1 2018-2.5%+5.8%-8.8%
Q4 2017-17.5%-18.3%-14.1%
Q3 2017+9.6%+11.6%+3.4%
Q2 2017-4.2%-1.5%-5.4%
Q1 2017-1.2%-9.1%+9.3%
Q4 2016+10.0%+10.2%+10.6%
Q3 2016-20.5%-3.5%+27.3%
Q2 2016-8.9%-8.1%-10.2%
Q1 2016+19.7%
Q4 2015-36.8%
Q3 2015-10.5%
Q2 2015+11.5%
Q1 2015+12.9%
Q4 2014-6.6%
Q3 2014+5.7%
Q2 2014+0.1%
Q1 2014-8.5%
Q3 2013-0.8%
Q2 2013+0.6%
Q1 2013-7.6%
Q4 2012-19.9%
Q3 2012-3.3%
Q2 2012-6.4%
Q1 2011-0.2%
Q1 2012+1.0%
Q4 2011-4.4%
Q3 2011-9.3%
Q3 2010-9.3%
Q2 2011-0.1%
Q2 2010-0.1%
Q4 2010-1.4%
Q1 2010+3.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro